Passage BIO, Inc. Update: A Major Merger Announcement

If you follow Passage BIO, Inc., a company developing genetic medicines for central nervous system (CNS) disorders, there is major news. The company has announced a merger with Remix Therapeutics, Inc., a biotech firm focused on small molecule therapies that target RNA.

This is a reverse merger. While Passage BIO remains the public company, the Remix team will lead the combined business.

1. What is changing?

• New Leadership: Remix CEO Peter Smith, Ph.D., will become CEO of the combined company. The board will have nine members, with most chosen by Remix.
• The Name: The company will rebrand as "Remix Therapeutics, Inc."
• The "Bonus" (CVRs): Current Passage BIO shareholders will receive one Contingent Value Right (CVR) for each share they own. These CVRs offer potential cash payments if the company sells or licenses its older gene therapy programs. Note: There is no guarantee these assets will be sold or that the CVRs will have any value.
• Operational Pivot: The company ended its manufacturing agreement with Catalent. This marks a shift away from the old Passage BIO model, which relied on expensive infrastructure for complex gene therapy.

2. Why is this happening?

In biotech, access to cash is vital for research. Passage BIO’s market value had dropped significantly, while Remix Therapeutics is valued at about $226 million. By merging, Passage BIO gives Remix a "public home" to access the stock market. The deal includes $100 million in new private funding to fuel the company’s research pipeline toward future clinical milestones.

3. Is the deal a "done deal"?

The merger still needs regulatory approval and a vote from Passage BIO stockholders.

• Support: Stockholders representing about 93% of Remix shares and key Passage BIO insiders have agreed to vote in favor of the deal.
• Lock-ups: To keep the stock stable, officers and directors from both companies signed "lock-up" agreements. They cannot sell or transfer their shares for 180 days after the merger closes. This shows that management is focused on the company’s long-term performance.

4. What should you watch for?

• Volatility: Mergers like this often cause price swings as the market adjusts to the new company’s value.
• The CVR "Lottery Ticket": CVRs cannot be traded on an exchange and offer no voting rights. They are a way to capture potential value from old assets, but they do not represent ownership in the new company.
• The Vote: Watch for the upcoming Proxy Statement. It will explain the final merger terms, the name change, and a possible reverse stock split. A reverse split would combine shares to keep the stock price high enough to meet exchange listing rules. The company hasn't provided specific details on the exact ratio for a potential split yet, so keep an eye on official filings for that number.

5. The Bottom Line

The "old" Passage BIO is being absorbed into the Remix platform. The new management team will decide which old programs, if any, continue. You are moving from an investment in gene therapy to a bet on the Remix team. They will use the $100 million in new funding to push their RNA-targeting pipeline toward clinical success.

Decision Checklist:

• Are you interested in the new leadership? Research Peter Smith and the Remix track record.
• Do you understand the CVRs? Remember, these are speculative and not guaranteed to pay out.
• Check the Proxy Statement: Before you make any final moves, read the official proxy statement when it is released—it contains the fine print that could impact your investment.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and shouldn't be taken as professional investment advice. Always do your own research before making any trades!